SEARCH

SEARCH BY CITATION

References

  • Brown, N. (2003) Hope against hype: accountability in biopasts, presents and futures, Science Studies, 16, 321.
  • Clark, C.C., Scott E.A., Boydell, K.M. and Goering, P. (1999) Effects of client interviewers on client reported satisfaction with mental health services, Psychiatric Services, 50, 9613.
  • Dobson, R. (2003) Pharmaceutical industry is main influence in GP prescribing, British Medical Journal, 326, 301.
  • Gaskell, G., Allansdottir, A., Allum, N., et al . (2006) Europeans and biotechnology in 2005: patterns and trends., Eurobarometer, 64, 3, Brussels.
  • Grime, J. and Pollock, K. (2003) Patients’ ambivalence about taking antidepressants: a qualitative study, The Pharmaceutical Journal, 271, 51618.
  • Hedgecoe, A. (2004) The Politics of Personalised Medicine: Pharmacogenetics in the Clinic. Cambridge: Cambridge University Press.
  • Hedgecoe, A. and Martin, P. (2003) The drugs don't work: expectations and the shaping of pharmacogenetics, Social Studies of Science, 33, 32764.
  • Horwitz, A. and Wakefield, J. (2007) The Loss of Sadness: how Psychiatry Transformed Normal Sorrow into Depressive Disorder. Oxford: Oxford University Press.
  • House of Commons (2005) The Influence of the Pharmaceutical Industry. Health Committee Fourth Report of Session 2004–2005 Volume I. London: The Stationery Office Limited.
  • Karp, D. (1997) Speaking of Sadness: Depression, Disconnection, and the Meanings of Illness. Oxford: Oxford University Press.
  • Karp, D. (2006) Is it Me or my Meds? Living with Antidepressants. Cambridge: Harvard University Press.
  • Kramer, P. (2005) Against Depression. New York: Penguin.
  • Kendell, R. (2001) The distinction between mental and physical illness, The British Journal of Psychiatry, 178, 4903.
  • Kitzinger, J. (1994) The methodology of focus groups: the importance of interaction between research participants, Sociology of Health and Illness, 16, 1, 103–21.
  • Lindpaintner, K. (2002) The impact of pharmacogenomics and pharmacogenomics on drug discovery, Nature Reviews, 1, 4639.
  • Martin, P., Lewis, G., Smart, A. and Webster, A. (2006) False Positive? The Commercial and Clinical Development of Pharmacogenetics. IGBis, SATSU, University of Nottingham.
  • Medicines and Healthcare Products Regulatory Agency (2004) Selective serotonin reuptake inhibitor (SSRI) antidepressants – findings of the Committee on Safety of Medicines (CSM) Working Group. Annex A – prescribing trends for SSRIs and related antidepressants. London: MHRA.
  • National Institute of Clinical Excellence (2003) Depression: Management of Depression in Primary and Secondary Care, Clinical Guideline 23. London: National Institute of Clinical Excellence.
  • Netzer, C. and Biller-Andorno, N. (2004) Pharmacogenomic testing: informed consent and the problem of secondary information, Bioethics, 18, 34460.
  • Nielsen, L.F. and Moldrup, C. (2007) The diffusion of innovation: factors influencing the uptake of pharmacogenetics, Community Genetics, 10, 23141.
  • Novas, C. (2006) The political economy of hope: patients’ organisations, science, and biovalue, Biosocieties, 1, 289305.
  • Pawlowski, T. and Kiejna, A. (2004) Pathways to psychiatric care and reform of the public health care system in Poland, European Psychiatry, 19, 16871.
  • Pieri, E. and Wynne, B. (2007) A qualitative study of personalised medicine: public priorities and values. ‘Genetics and Society: Retrospects and Prospects’. CESAGen/CSG 4th International Conference, 26th–28th March 2007, The Royal Society, London.
  • Rogausch, A., Prause, D., Schallenberg, A., Brockmöller, J. and Himmel, W. (2006) Patients’ and physicians’ perspectives on pharmacogenetic testing, Pharmacogenomics, 7, 4959.
  • Rose, D., Wykes, T., Leese, M., Bindman, J. and Fleischmann, P. (2003) Patients’ perspectives on electroconvulsive therapy: systematic review, British Medical Journal, 326, 13636.
  • Rose, N. (2005) Psycho-pharmaceuticals in Europe. In Knapp, M., McDaid, D., Mossialos, E. and Thornicroft, G. (eds) Mental Health Policy and Practice across Europe. Maidenhead: Open University Press.
  • Roses, A.D. (2000) Pharmacogenomics and the practice of medicine, Nature, 405, 85765.
  • Rothstein, M.A. and Hornung, C.A. (2003) Public attitudes about pharmacogenomics. In Rothstein, M.A. (ed.) Pharmacogenomics: Social, Ethical, and Clinical Dimensions. Hoboken, NJ: John Wiley and Sons.
  • Royal Society (2005a) Personalised Medicines: Hopes and Realities. London: Royal Society.
  • Royal Society (2005b) Pharmacogenetics: Dialogue. London: Royal Society.
  • Shorter, E. (2005) The historical development of mental health services in Europe. In Knapp, M., McDaid, D., Mossialos, E. and Thornicroft, G. (eds) Mental Health Policy and Practice across Europe. Maidenhead: Open University Press.
  • Silverman, D. (2000) Doing Qualitative Research. London: SAGE.
  • Smart, A., Martin, P. and Parker, M. (2004) Tailored medicine: whom will it fit? Ethics of patient and disease stratification, Bioethics, 18, 32243.
  • Solomon, A. (2002) The Noonday Demon: an Anatomy of Depression. London: Vintage Books.
  • Vedantam, S. (2004) Antidepressant use by US adults soars, Washington Post 3rd December, A15.
  • Wilkinson, S. (2005) Analysing interaction in focus groups. In Drew, P., Raymond, G. and Weinberg, D. (eds) Talking Research. London: SAGE.
  • World Health Organization (2001) World Health Report 2001. Geneva: World Health Organization.